Alterity Therapeutics Doses First Patient in ATH434 Phase 2

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

Related Keywords

New Zealand , Australia , California , United States , Melbourne , Victoria , San Francisco , Tim Anderson , David Stamler , Company Phase , National Institute Of Health , European Commission , Alterity Therapeutics , Nasdaq , Zealand Brain Research Institute , Multiple System Atrophy , Chief Executive Officer , New Zealand Brain Research Institute , Professor Tim Anderson , Lead Investigator , New Zealand Brain Research , System Atrophy , Neurological Disorders , Multiple System Atrophy Fact , Biotechnology , Health Care Amp Hospitals , Medical Pharmaceuticals , Pharmaceuticals , Clinical Trials Amp Medical Discoveries ,